198904-31-3

• 常用中文名：阿扎那韦
• 常用英文名：Atazanavir
• CAS号：198904-31-3
• 分子式：C₃₈H₅₂N₆O₇
• 分子量：704.856
• 相关类别： 原料药 抗生素类药物 其它抗生素类药
• 发布时间：2018-04-05 08:00:00
• 更新时间：2026-06-30 19:41:25
• Atazanavir(BMS-232632)是HIV-1蛋白酶高活性抑制剂。

名称

• 中文名: 阿扎那韦
• 英文名: atazanavir
• 中文别名: 阿扎那韦碱; 扎那韦双硫酸盐; 阿扎那韦(对照品); 1,14-二甲基 (3S,8S,9S,12S)-3,12-双(1,1-二甲基乙基)-8-羟基-4,11-二氧代-9-(苯基甲基)-6-[[4-(2-吡啶基)苯基]甲基]-2,5,6,10,13-五氮杂十四烷二酸酯; 阿扎那韦杂质; 阿扎那韦,10 MM DMSO 溶液; ATAZANAVIR 阿扎那韦; 阿扎那韦手性异构体3; 阿扎那韦游离碱; 阿扎那韦(标准品); 阿札那韦; 阿扎那韦中间体杂质4; 阿扎那韦中间体杂质3; 阿扎那韦中间体杂质2; 阿扎那韦双硫酸盐; 阿扎那韦中间体杂质1; 阿扎那韦手性异构体2; 阿扎那韦手性异构体1; Atazanavir 5mg试剂; 阿扎那韦对映异构体; 阿扎那韦手性异构体
• 英文别名: Zrivada; Atv; (2S)-N-(3-{[(2S)-2-(Methoxycbonylamino)-3,3-dimethylbutanoylamino][(4-(2-pyridyl)phenyl)methyl]amino}(1S,2S)-2-hydroxy-1-benzylpropyl)-2-(methoxycbonylamino)-3,3-dimethylbutanamide; BMS 232632 - Atazanavir | CGP; Atazanavir， min; 3,12-Bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-dimethyl Ester; Atazanavir Base; (3S,8S, 9S, 12S)-2,5,6,13-Pentaazatetradecanedioic Acid; BMS-232632(Atazanavir); Methyl [(5S,10S,11S,14S)-11-Benzyl-5-tert-butyl-10-hydroxy-15,15-dimethyl-3,6,13-trioxo-8-[4-(2-pyridinyl)benzyl]-2-oxa-4,7,8,12-tetraazahexadecan-14-yl]cbamate; Aids057755; Atazanavir - Bio-X; 2,5,6,10,13-Pentaazatetradecanedioicacid,3,12-bis(1,1-diMethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylMethyl)-6-[[4-(2-pyridinyl)phenyl]Methyl]-,1,14-diMethyl ester, (3S,8S,9S,12S); Atazanavir (10mM in DMSO); Atazanavir Enantiomer; Atazanavir Intermediate Impurity 3; Atazanavir Intermediate Impurity 4; Atazanavir Intermediate Impurity 1; Methyl N-[(2S)-1-[[(2S,3S)-3-hydroxy-4-[[[(2S)-2-(MethoxycbonylaMino); Atazanavir Intermediate Impurity 2; 1,14-Dimethyl (3S,8S,9S,12S)-3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-[[4-(2-pyridinyl)phenyl]methyl]-2,5,6,10,13-pentaazatetradecanedioate; [3H]-Atazanavir; Atazanavir free base; (3S,8S,9S,12S)-3,12-Bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-2,5,6,10,13-pentaazatetradecanedioic acid Dimethyl Ester; Methyl {(5S,10S,11S,14S)-11-benzyl-10-hydroxy-15,15-dimethyl-5-(2-methyl-2-propanyl)-3,6,13-trioxo-8-[4-(2-pyridinyl)benzyl]-2-oxa-4,7,8,12-tetraazahexadecan-14-yl}carbamate; 229-7 (Sulfate 1:1); EOS-60363; Atazanavir Isomer Impurity; Aids-057755; Azanavir; Latazanavir; BMS-232632-05; REYATAZ;BMS23263205; atazanvir; Atazanavir iMpurity; 2aqu; Dimethyl (3S,8S,9S,12S)-9-benzyl-3,12,di-tert-butyl-8-hydroxy-4,11-dioxo-6-(p-2-pyridylbenzyl)-2,5,6,10,13-pentaazatetradecanedioate; Methyl N-[(2S)-1-[[(2S,3S)-3-hydroxy-4-[[[(2S)-2-(methoxycbonylamino)-3,3-dimethylbutanoyl]a; Methyl N-[(2S)-1-[[(2S,3S)-3-hydroxy-4-[[[(2S)-2-(methoxycbonylamino)-3,3-dimethylbutanoyl]amino]-[(4-pyridin-2-ylphenyl)methyl]amino]-1-phenylbutan-2-yl]amino]-3,3-dimethyl-1-oxobutan-2-yl]cbamate; Atazanavir //BP; (3S-(3R*,8R*,9R*,12R*))-3,12-Bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-2,5,6,10,13-pentaazatetradecanedioic acid Dimethyl Ester; Atazanavir API; Reyataz; UNII-QZU4H47A3S; methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycarbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate; Methyl {(5S,10S,11S,14S)-11-benzyl-5-tert-butyl-10-hydroxy-15,15-dimethyl-3,6,13-trioxo-8-[4-(pyridin-2-yl)benzyl]-2-oxa-4,7,8,12-tetraazahexadecan-14-yl}carbamate; methyl N-[(2S)-1-[2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-(methoxycbonylamino)-3,3-dimethylbutanoyl]amino]-4-phenylbutyl]-2-[(4-pyridin-2-ylphenyl)methyl]hydrazinyl]-3,3-dimethyl-1-oxobutan-2-yl]cbamate; ATAZANAVIR, BISULFATE SALT; BMS-232632-05; methyl((5S,10S,11S,14S)-11-benzyl-5-(tert-butyl)-10-hydroxy-15,15-dimethyl-3,6,13-trioxo-8-(4-(pyridin-2-yl)benzyl)-2-oxa-4,7,8,12-tetraazahexadecan-14-yl)cbamate; Atazanavir & Atazanavir Sulfate; Atazanavir Isomer Impurity 1; Methyl-{(5S,10S,11S,14S)-11-benzyl-5-tert-butyl-10-hydroxy-15,15-dimethyl-3,6,13-trioxo-8-[4-(pyridin-2-yl)benzyl]-2-oxa-4,7,8,12-tetraazahexadecan-14-yl}carbamat; Atazanavir Isomer Impurity 2; butanoic acid, 2-[(methoxycarbonyl)amino]-3,3-dimethyl-, 2-[(2S,3S)-2-hydroxy-3-[[(2S)-2-[(methoxycarbonyl)amino]-3,3-dimethyl-1-oxobutyl]amino]-4-phenylbutyl]-2-[[4-(2-pyridinyl)phenyl]methyl]hydrazi; Atazanavir, >=; Atazanavir Isomer Impurity 3; 198-3; Atazanavir(BMS-232632); Methyl {(5S,10S,11S,14S)-11-benzyl-5-tert-butyl-10-hydroxy-15,15-dimethyl-3,6,13-trioxo-8-[4-(pyridin-2-yl)benzyl]-2-oxa-4,7,8,12-tetraazahexadecan-14-yl}carbamate (non-preferred name)

物化性质

• 密度: 1.2±0.1 g/cm3
• 熔点: 207-209ºC
• 分子式: C₃₈H₅₂N₆O₇
• 分子量: 704.856
• 精确质量: 704.389771
• PSA: 171.22000
• LogP: 5.20
• 外观性状: 结晶固体
• 折射率: 1.562
• 储存条件: -20°C;存放于惰性气体之中;避免空气,加热

生物活性

• 描述: Atazanavir(BMS-232632)是HIV-1蛋白酶高活性抑制剂。
• 相关类别:
  信号通路 >> 代谢酶/蛋白酶 >> HIV蛋白酶
  信号通路 >> 抗感染 >> HIV
  研究领域 >> 感染
• 参考文献:

  [1]. Gianotti N, Soria A, Lazzarin A. Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review. New Microbiol. 2007 Apr;30(2):79-88.

  [2]. von Hentig N. Atazanavir/ritonavir: a review of its use in HIV therapy. Drugs Today (Barc). 2008 Feb;44(2):103-32.

  [3]. Wood R. Atazanavir: its role in HIV treatment. Expert Rev Anti Infect Ther. 2008 Dec;6(6):785-96.

  [4]. Croom KF, Dhillon S, Keam SJ. Atazanavir: a review of its use in the management of HIV-1 infection. Drugs. 2009 May 29;69(8):1107-40.

  [5]. Bentué-Ferrer D, Arvieux C, Tribut O et al. Clinical pharmacology, efficacy and safety of atazanavir: a review. Expert Opin Drug Metab Toxicol. 2009 Nov;5(11):1455-68.

  [6]. Atazanavir

安全

• 危害码 (欧洲): Xi

合成路线

上下游产品

上游产品  8
857904-02-0 79-22-1 127406-56-8 109-04-6
24856-58-4 20859-02-3 857904-11-1 857900-54-0
下游产品  0